{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:41:15Z","timestamp":1792514475873,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.anndiagpath.2024.152332","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:58:45Z","timestamp":1715965125000},"page":"152332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Evaluation of tubulin \u03b2-3 and 5 hydroxy-methyl cytosine as diagnostic and prognostic markers in malignant melanoma"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8956-1861","authenticated-orcid":false,"given":"Lundmark","family":"Katarzyna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orfanidis","family":"Kyriakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4371-1238","authenticated-orcid":false,"given":"Vainikka","family":"Linda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synnerstad","family":"Ingrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-3290","authenticated-orcid":false,"given":"W\u00e4ster","family":"Petra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4075-159X","authenticated-orcid":false,"given":"\u00d6llinger","family":"Karin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2024.152332_bb0005","article-title":"Pathologists\u2019 diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study","volume":"357","author":"Elmore","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1600-0560.2007.00970.x","article-title":"Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting","volume":"35","author":"Lodha","year":"2008","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.path.2021.01.001","article-title":"PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions","volume":"14","author":"Lezcano","year":"2021","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0020","doi-asserted-by":"crossref","first-page":"853","DOI":"10.5858\/2009-0717-RAR.1","article-title":"Immunohistochemistry of melanocytic proliferations","volume":"135","author":"Prieto","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0025","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1038\/onc.2017.189","article-title":"Melanocytic nevi and melanoma: unraveling a complex relationship","volume":"36","author":"Damsky","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2014.09.028","article-title":"Outcome of patients with de novo versus nevus-associated melanoma","volume":"72","author":"Lin","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0035","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2133.2008.08887.x","article-title":"RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis","volume":"160","author":"Dadzie","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/pcmr.12572","article-title":"Evaluation of tubulin \u03b2-3 as a novel senescence-associated gene in melanocytic malignant transformation","volume":"30","author":"Orfanidis","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0045","article-title":"An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance","volume":"18","author":"Parker","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diff.2013.05.003","article-title":"Class III \u03b2-tubulin, a novel biomarker in the human melanocyte lineage","volume":"85","author":"Locher","year":"2013","journal-title":"Differentiation"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0055","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2012.45.3282","article-title":"Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status","volume":"31","author":"Edelman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2024.152332_rf0110","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-05-2715","article-title":"Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients","volume":"12","author":"Ferrandina","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2024.152332_rf0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/modpathol.2016.159","article-title":"5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma","volume":"30","author":"Saldanha","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0065","first-page":"1629","article-title":"Expression of class III beta-tubulin predicts prognosis in patients with cisplatin-resistant bladder cancer receiving paclitaxel-based second-line chemotherapy","volume":"38","author":"Miyata","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0070","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ajpath.2013.11.007","article-title":"\u03b2III-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion","volume":"184","author":"Tsourlakis","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0075","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/jid.2008.406","article-title":"Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells","volume":"129","author":"Akasaka","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CMR.0000000000000208","article-title":"Decreased expression of class III\u03b2-tubulin is associated with unfavourable prognosis in patients with malignant melanoma","volume":"26","author":"Shimizu","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2017.10.006","article-title":"Epigenetics of malignant melanoma","volume":"51","author":"Moran","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.18632\/oncotarget.316","article-title":"Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem\/progenitor cell compartments and in human cancers","volume":"2","author":"Haffner","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CMR.0000000000000349","article-title":"The role of 5-hydroxymethylcytosine in melanoma","volume":"27","author":"Li","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0100","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cell.2012.07.033","article-title":"Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma","volume":"150","author":"Lian","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0105","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/modpathol.2013.224","article-title":"Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors","volume":"27","author":"Larson","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0115","unstructured":"Elder DE, Barnhill RL, Bastian BC, et al. Melanocytic tumour classification and the pathway concept of melanoma pathogenesis. In: Elder DE, Massi D,Scolyer RA, Willemze R, editors. WHO classification of skin Tumours. 4th ed. Lyon,France: IARC; 2018:66\u201371. [World Health Organization Classification of Tumours;vol 11]."},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1126\/science.1127515","article-title":"MC1R germline variants confer risk for BRAF-mutant melanoma","volume":"313","author":"Landi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0125","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0130","first-page":"705","article-title":"The histogenesis and biologic behavior of primary human malignant melanomas of the skin","volume":"29","author":"Clark","year":"1969","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0135","series-title":"AJCC Cancer staging manual","first-page":"563","article-title":"Melanoma of the skin","author":"Gershenwald","year":"2017"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/cup.12880","article-title":"5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms","volume":"44","author":"Lee","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0145","first-page":"1","article-title":"Current state of adjuvant therapy for melanoma","volume":"42","author":"Lao","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0150","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/cncr.32585","article-title":"Considering adjuvant therapy for stage II melanoma","volume":"126","author":"Poklepovic","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0155","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00428-009-0764-4","article-title":"Beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion","volume":"454","author":"Portyanko","year":"2009","journal-title":"Virchows Arch"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0165","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00428-019-02533-9","article-title":"\u03b2-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors","volume":"474","author":"de la Fouchardi\u00e8re","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0170","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002594R","article-title":"Microtubule-targeting agents impair kinesin-2-dependent nuclear transport of \u03b2-catenin: evidence of inhibition of Wnt\/\u03b2-catenin signaling as an important antitumor mechanism of microtubule-targeting agents","volume":"35","author":"Kumari","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0175","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1186\/s12864-017-4091-x","article-title":"5-Hydroxymethylcytosine is highly dynamic across human fetal brain development","volume":"18","author":"Spiers","year":"2017","journal-title":"BMC Genomics"},{"key":"10.1016\/j.anndiagpath.2024.152332_bb0180","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/cup.12564","article-title":"Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations","volume":"42","author":"Rodic","year":"2015","journal-title":"J Cutan Pathol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913424000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913424000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T07:58:34Z","timestamp":1716537514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913424000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"alternative-id":["S1092913424000698"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2024.152332","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of tubulin \u03b2-3 and 5 hydroxy-methyl cytosine as diagnostic and prognostic markers in malignant melanoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2024.152332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152332"}}